We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$4.05B
AUM Growth
+$503M
Cap. Flow
+$454M
Cap. Flow %
11.2%
Top 10 Hldgs %
55.84%
Holding
654
New
120
Increased
131
Reduced
191
Closed
155

Sector Composition

Rank Sector Weight
1 Energy 20.91%
2 Technology 19.62%
3 Healthcare 14.36%
4 Industrials 11.13%
5 Consumer Staples 9.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SEDA.WS
476
DELISTED
SDCL EDGE Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary share at an exercise price of $11.50
SEDA.WS
$4.75K ﹤0.01%
47,479
-1,534
-3% -$164
BMRN icon
477
CALL
BioMarin Pharmaceuticals
BMRN
$12.1B
$4.13K ﹤0.01%
15,000
-25,000
-63% -$2.09M
RDZNW icon
478
Roadzen Inc Warrants
RDZNW
$8.64M
$4.11K ﹤0.01%
65,696
-1,485
-2% -$113
RMCOW icon
479
Royalty Management Holding Warrant
RMCOW
$1.16M
$3.68K ﹤0.01%
221,686
-4,893
-2% -$82
NVO
480
CALL
Novo Nordisk
NVO
$209B
$3.63K ﹤0.01%
25,000
-10,000
-29% -$1.33M
SDGR icon
481
CALL
Schrodinger
SDGR
$1.33B
$3K ﹤0.01%
30,000
-40,000
-57% -$822K
FNVTW
482
DELISTED
Finnovate Acquisition Corp. Warrants
FNVTW
$2.39K ﹤0.01%
127,590
-2,816
-2% -$51
OPTXW icon
483
Syntec Optics Holdings Warrant
OPTXW
$16.2M
$2.32K ﹤0.01%
32,034
-1,035
-3% -$112
GSK icon
484
CALL
GSK
GSK
$106B
$2.25K ﹤0.01%
30,000
-40,000
-57% -$1.64M
TVGNW icon
485
Tevogen Inc. Warrant
TVGNW
$812K
$2.19K ﹤0.01%
181,387
-4,029
-2% -$79
MNTN.WS
486
DELISTED
Everest Consolidator Acquisition Corporation Warrants, each whole warrant exercisable for one share of Class A Common Stock, at an exercise price of $11.50
MNTN.WS
$2.16K ﹤0.01%
76,252
-2,464
-3% -$249
UGI icon
487
PUT
UGI
UGI
$7.43B
$1.79K ﹤0.01%
71,700
MCAAW
488
DELISTED
Mountain & Co. I Acquisition Corp. Warrant
MCAAW
$1.77K ﹤0.01%
133,215
-2,940
-2% -$121
VST icon
489
PUT
Vistra
VST
$46.1B
$698 ﹤0.01%
27,900
WINVW
490
DELISTED
WinVest Acquisition Corp. Warrant
WINVW
$257 ﹤0.01%
17,995
-397
-2% -$6
ABNB icon
491
Airbnb
ABNB
$104B
-22,500
Closed -$3.41M
AEP icon
492
American Electric Power
AEP
$68.4B
-91,000
Closed -$7.98M
ALNY icon
493
CALL
Alnylam Pharmaceuticals
ALNY
$28.6B
-10,000
Closed -$46K
ALNY icon
494
PUT
Alnylam Pharmaceuticals
ALNY
$28.6B
-19,100
Closed -$27.9K
APD icon
495
Air Products & Chemicals
APD
$66.9B
-44,500
Closed -$11.5M
APH icon
496
Amphenol
APH
$207B
-189,100
Closed -$12.7M
ARDX icon
497
PUT
Ardelyx
ARDX
$1.02B
-100,000
Closed -$37.5K
ASML icon
498
ASML
ASML
$667B
-2,863
Closed -$2.93M
AXSM icon
499
CALL
Axsome Therapeutics
AXSM
$10.9B
-15,000
Closed -$46.9K
AZEK
500
DELISTED
The AZEK Co
AZEK
-133,200
Closed -$5.61M

Similar funds

UBS O'Connor's Q3 2024 Portfolio in Review

As of Q3 2024, UBS O'Connor held 654 positions worth $4.05B, up 14% from $3.55B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

UBS O'Connor deployed $454M of net new capital in Q3 2024, opening 120 new positions and adding to 131 existing holdings. Its largest new stake was Kellanova: 3,778,689 shares worth $305M.

By sector, the portfolio is most concentrated in Energy at 21% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was US Steel, an estimated $20.2M trimmed.

  • UBS O'Connor's largest Q3 2024 buy was Kellanova: 3,778,689 shares worth $305M.
  • UBS O'Connor added most to Stericycle Inc in Q3 2024, an estimated $141M increase.
  • UBS O'Connor's biggest Q3 2024 reduction was US Steel, cutting an estimated $20.2M.
  • UBS O'Connor fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $149M.
  • UBS O'Connor's ten largest holdings make up 56% of its $4.05B portfolio in Q3 2024.
  • UBS O'Connor opened 120 new positions and closed 155 in Q3 2024.
  • UBS O'Connor's portfolio value rose 14% quarter-over-quarter to $4.05B.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.